JP6924429B2 - 眼科用薬物の定量的な眼窩周囲への適用 - Google Patents

眼科用薬物の定量的な眼窩周囲への適用 Download PDF

Info

Publication number
JP6924429B2
JP6924429B2 JP2018502246A JP2018502246A JP6924429B2 JP 6924429 B2 JP6924429 B2 JP 6924429B2 JP 2018502246 A JP2018502246 A JP 2018502246A JP 2018502246 A JP2018502246 A JP 2018502246A JP 6924429 B2 JP6924429 B2 JP 6924429B2
Authority
JP
Japan
Prior art keywords
eye
orbit
fluoro
days
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018502246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528169A5 (enExample
JP2018528169A (ja
Inventor
ウッドワード，デイビッド
ワン，ウェイツェン
Original Assignee
ジェニヴィジョン インク．
ジェニヴィジョン インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェニヴィジョン インク．, ジェニヴィジョン インク． filed Critical ジェニヴィジョン インク．
Publication of JP2018528169A publication Critical patent/JP2018528169A/ja
Publication of JP2018528169A5 publication Critical patent/JP2018528169A5/ja
Application granted granted Critical
Publication of JP6924429B2 publication Critical patent/JP6924429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
JP2018502246A 2015-08-19 2016-08-17 眼科用薬物の定量的な眼窩周囲への適用 Active JP6924429B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/829,789 US9820954B2 (en) 2015-08-19 2015-08-19 Quantitative peri-orbital application of ophthalmology drugs
US14/829,789 2015-08-19
PCT/US2016/047230 WO2017031137A1 (en) 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs

Publications (3)

Publication Number Publication Date
JP2018528169A JP2018528169A (ja) 2018-09-27
JP2018528169A5 JP2018528169A5 (enExample) 2019-09-26
JP6924429B2 true JP6924429B2 (ja) 2021-08-25

Family

ID=58051248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018502246A Active JP6924429B2 (ja) 2015-08-19 2016-08-17 眼科用薬物の定量的な眼窩周囲への適用

Country Status (9)

Country Link
US (1) US9820954B2 (enExample)
EP (1) EP3337474A4 (enExample)
JP (1) JP6924429B2 (enExample)
KR (1) KR102685479B1 (enExample)
CN (1) CN108135873A (enExample)
AU (1) AU2016308105B2 (enExample)
CA (1) CA2992483C (enExample)
MX (1) MX391627B (enExample)
WO (1) WO2017031137A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827225B2 (en) 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
WO2019005139A1 (en) * 2017-06-30 2019-01-03 Jenivision Inc. FORMULATIONS FOR HAIR GROWTH
GB2597731A (en) * 2020-07-31 2022-02-09 Imperial College Innovations Ltd Preterm labour
JP2024506872A (ja) * 2021-02-05 2024-02-15 ジェニヴィジョン インク． Ｅｐ２受容体アゴニストの眼窩周囲投与のための組成物および方法
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases
CN116869991A (zh) * 2023-06-06 2023-10-13 南昌大学 柚皮素在制备治疗和/或预防眼部疾病的药物中的用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3990444A (en) 1972-11-22 1976-11-09 Vial S.A.R.L. Blood transfusion apparatus
US4131115A (en) 1976-09-20 1978-12-26 Peng Sung S Eyelids-turning and eye-washing fixture
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
ATE109970T1 (de) 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
EP1723132A1 (en) 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
JP2007534384A (ja) 2004-04-23 2007-11-29 ミスティック ファーマシューティカルズ， インコーポレイテッド 複数の単位用量の薬物送達システム
US7226435B2 (en) 2004-10-14 2007-06-05 Alcon, Inc. Drug delivery device
AU2006254825A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
US20070016256A1 (en) 2005-07-18 2007-01-18 Korb Donald R Method and apparatus for treating gland dysfunction
WO2007095486A1 (en) 2006-02-13 2007-08-23 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
CA2650592A1 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
WO2008026756A1 (en) 2006-08-28 2008-03-06 Senju Pharmaceutical Co., Ltd. Ophthalmic percutaneous absorption type preparation
AU2007313684A1 (en) * 2006-10-31 2008-05-08 Alcon Research, Ltd. PAI-1 binding modulators for the treatment of ocular disorders
DK2173407T3 (da) 2007-07-02 2020-04-27 Hoffmann La Roche Anordning til indgivelse af lægemiddel
TW200927169A (en) * 2007-11-07 2009-07-01 Alcon Res Ltd Complement Clq inhibitors for the prevention and treatment of glaucoma
MX2010005012A (es) 2007-11-08 2010-06-23 Aciex Therapeutics Inc Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
MX2010008226A (es) * 2008-02-05 2010-10-25 Asterand Uk Ltd Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP2493475A4 (en) 2009-10-30 2014-10-29 Intratus Inc COSMETIC METHODS AND PREPARATIONS FOR THE PROLONGED RELEASE OF THERAPEUTIC AGENTS IN THE EYE
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
EP2544757A4 (en) 2010-03-09 2013-11-06 Toxcure Inc MICRONADEL DEVICE FOR NASAL DISTRIBUTION
US9199066B2 (en) 2010-03-12 2015-12-01 Quattro Vascular Pte Ltd. Device and method for compartmental vessel treatment
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
GB2482691B (en) 2010-08-10 2013-08-14 Nemaura Pharma Ltd Structures for transdermal drug delivery
US8900626B2 (en) 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
JP2014530177A (ja) * 2011-09-16 2014-11-17 フオベア・フアルマシユテイカル アニリン誘導体、それらの調製およびそれらの治療適用
AU2012339695B2 (en) 2011-11-15 2017-10-05 Allergan, Inc. Sustained action formulation of cyclosporin Form 2
WO2014045300A2 (en) 2012-09-03 2014-03-27 Fdc Limited "topical drug delivery system"
CN203379477U (zh) 2012-12-14 2014-01-08 上海市第七人民医院 一种微针滚轮装置

Also Published As

Publication number Publication date
KR20180042348A (ko) 2018-04-25
AU2016308105B2 (en) 2021-05-27
CA2992483A1 (en) 2017-02-23
AU2016308105A1 (en) 2018-02-15
CN108135873A (zh) 2018-06-08
US20170049734A1 (en) 2017-02-23
CA2992483C (en) 2024-03-19
EP3337474A1 (en) 2018-06-27
MX2018001918A (es) 2018-11-09
WO2017031137A1 (en) 2017-02-23
MX391627B (es) 2025-03-21
JP2018528169A (ja) 2018-09-27
EP3337474A4 (en) 2019-04-10
KR102685479B1 (ko) 2024-07-15
US9820954B2 (en) 2017-11-21

Similar Documents

Publication Publication Date Title
JP6924429B2 (ja) 眼科用薬物の定量的な眼窩周囲への適用
EP2389221B1 (en) Sustained released delivery of one or more agents
EP3290024B1 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US9949942B2 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US20090318549A1 (en) Combination treatment of glaucoma
US9974685B2 (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP2844224B1 (en) Drug delivery system for treating open angle glaucoma and ocular hypertension
CN117062602A (zh) 用于ep2受体激动剂的眶周施用的组合物和方法
HK1162151B (en) Sustained released delivery of one or more agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210621

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210716

R150 Certificate of patent or registration of utility model

Ref document number: 6924429

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250